Home Page
Site Map
Newsletter
About
Creabilis
Mission &
Strategy
Board of
Directors
Management
Investors
History
Pipeline
Projects
Creabilis Science
MiniPEGylation
Targets
Drug Discovery
Contacts
Information Request
Board of directors
Alfredo Boni,
President
Graziano Seghezzi,
Sofinnova Partners
Claudio Nessi,
NeoMed Management
Pipeline
CT500
The CT500 program is aimed at inflammatory disorders includi ...
CT400
The CT400 program is aimed at developing inhibitors of HGMB- ...
CT327
Is being developed as a novel topical treatment for psoriasi ...
more
News & Events
2008-10-13
CREABILIS
therapeutics
Announces Establishment of Sci ...
2008-06-16
CREABILIS
therapeutics
Appoints Anthony Wilson as its ...
2008-06-06
CREABILIS
therapeutics
Raises €20 Million in a Series ...
more
